Ketalux - Ketamine Therapy EducationKetalux - Mental Wellness Authority
FDA · Final action

Racemic ketamine has no FDA-approved psychiatric indication

Generic (racemic) ketamine is approved as an anesthetic agent. Its use for depression, PTSD, anxiety, chronic pain, or other psychiatric indications is off-label prescribing, which is lawful for licensed clinicians but is not the same as FDA approval for that use.

Written by: Ira ZootMedical review status: Pending clinical reviewLast updated: August 24, 2026Evidence: Primary government source

Record details

Agency
FDA
Jurisdiction
United States (federal)
Status
Final action
Published
Ongoing status
Effective
Not applicable / not verified
Expires
Not applicable / not verified
Last checked
August 24, 2026

Why it matters

Off-label status affects insurance coverage, the absence of a REMS framework, and the wide variation in protocols between clinics.

Primary source

FDA — Understanding unapproved use of approved drugs (off-label)

Not legal advice
Regulatory information is educational and may change. Verify current requirements with the appropriate agency or qualified counsel. Ketalux does not provide legal advice.

Back to the Regulatory Tracker.

About the author

Founder and publisher of Ketalux, based in Chicago, Illinois. Ketalux.com is owned and operated by iDigits LLC. Ira commissions and edits the site's articles and believes ketamine therapy — used responsibly — offers real hope for people living with depression, anxiety, PTSD, and chronic pain. Contact: ira@idigits.com.

Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.